PTJA07 Pharmaceutical Joint Assessment Now Available – ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response with, lost response to or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
This is the pharmaceutical Joint Assessment PTJA07 – on ustekinumab for the treatment of ulcerative colitis (UC). In September 2019, EMA approved the extension of the indication for ustekinumab to include treatment of adult patients with moderately to severely active
The EUnetHTA Executive Board recently adopted the following Understanding of EUnetHTA HTA. This text is the result of several months of consultation with the project's board. The EUnetHTA Executive Board agreed that HTA in the context of EUnetHTA activities is understood
We are pleased to announce that the final assessment report for OTJA10 'Stool DNA testing for early detection of colorectal cancer', together with the fact check comments from manufacturers and comments from external experts including the replies of the author,
EUnetHTA is pleased to announce the publication of the second iteration of the EPL. As part of the overarching Topic Identitication, Selection and Prioritisation (TISP) task group, the EPL is a valuable strategic tool for companies to identify the significant
The public consultation of the draft methodological guideline “Practical considerations when critically assessing economic evaluations” is OPEN (deadline Oct. 11, 2019)
We are pleased to announce that, as of today, the draft methodological guideline "Practical considerations when critically assessing economic evaluations", produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019. Objective of the
Public consultation on the guideline ”Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” in August/September 2019
The methodological guideline ''Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is currently under revision by IQWiG, NIPHNO and AETSA. It will be made available for public consultation as of beginning of August for
Reminder: Open Call for Patient Input – Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD).
This is a friendly reminder that EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Please be advised that input submissions will be received through
We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access. Irreversible electroporation (IRE) is a nonthermal ablative method based on